Pyxis Oncology Inc. (NASDAQ: PYXS) on Thursday released preliminary data from its ongoing Phase 1 studies of micvotabart pelidotin (MICVO) for recurrent/metastatic head and neck squamous cell ...
BOSTON - Pyxis Oncology, Inc. (NASDAQ:PYXS) announced preliminary data from ongoing Phase 1 clinical studies of its antibody-drug conjugate micvotabart pelidotin (MICVO) in patients with ...
Pyxis secured S$13 million in the first close of its S$18 million growth funding round, reflecting strong investor confidence in its vessel technology, commercial traction, and regional growth ...
SINGAPORE - Media OutReach Newswire - 22 December 2025 - Pyxis, a leading Singapore-based maritime electrification startup, has secured S$13 million in the first close of its S$18 million growth ...
46% confirmed objective response rate (ORR) and 92% disease control rate (DCR) observed with MICVO as monotherapy in 2L+ R/M HNSCC at 5.4 mg/kg 71% confirmed ORR and 100% DCR observed with MICVO in ...
Ashvin Gandhi ([email protected]) is an assistant professor at the University of California Los Angeles Anderson School of Management, in Los Angeles, California. Huizi Yu is an undergraduate student ...
The BSN Pathway is built on a traditional four-year undergraduate curriculum that provides a foundational education that includes both academic and professional nursing courses essential for clinical ...
Graduates of the MSN Neonatal Nurse Practitioner (NNP) Specialty are prepared for advanced nursing practice to diagnose and manage the health problems of newborns, infants and toddlers up to the age ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback